Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Machine learning-driven exploration of drug therapies for triple-negative breast cancer treatment

Frontiers in Molecular Biosciences(2023)10.3389/fmolb.2023.1215204Source: DataRank Database

Machine learning-driven exploration of drug therapies for triple-negative breast cancer treatment is a research paper published in Frontiers in Molecular Biosciences (2023). On theSindex it has a DataRank of 0. It has been cited 2 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access2 citations

Download PDF

Cite:

Linked data & code

ensembl doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)Impact (FWCI 0.42)OA: goldTopics (39)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (2)

Zhongming Zhao ORCID,Aman Chandra Kaushik ORCID

Live enrichment

PubMed:37602329 PMC:PMC10436744 OpenAlex:https://openalex.org/W4385578916

National Institutes of Health

Grant: 1R01LM012806-01

Predicting Phenotype by Using Transcriptomic Alteration as Endophenotype

FWCI

0.42

Citation Percentile

0.6%

Citation Trend

2025

2026

goldLicense: cc-by

journalhttps://www.frontiersin.org/articles/10.3389/fmolb.2023.1215204/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fmolb.2023.1215204/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fmolb.2023.1215204/full

journalhttps://doi.org/10.3389/fmolb.2023.1215204

repositoryhttps://pubmed.ncbi.nlm.nih.gov/37602329

Fields of Study

Computational Drug Discovery MethodsHER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations03 medical and health sciences0302 clinical medicine

Keywords

Triple-negative breast cancerBreast cancerLapatinibMedicineCancerOncologyEstrogen receptorTamoxifenTargeted therapyInternal medicinePrecision medicinePersonalized medicineCancer researchBioinformaticsBiologyPathologyTrastuzumabPharmacogenomicsDrug sensitivitySetd7SrarpYipf5Medical SciencesQH301-705.5Cell PhenomenaObstetrics and Gynecology610Biomedical InformaticsMedical SpecialtiesMedicine and Health Sciencesand ImmunityMolecular BiosciencesBiology (General)Biological Phenomena

Sustainable Development Goals

SDG 0: Good health and well-being